{"log_id": 5209622548978355897, "direction": 0, "words_result_num": 28, "words_result": [{"probability": {"variance": 6e-06, "average": 0.997369, "min": 0.992654}, "location": {"width": 133, "top": 127, "height": 30, "left": 124}, "words": "【注意事项】"}, {"probability": {"variance": 2e-06, "average": 0.998716, "min": 0.996242}, "location": {"width": 151, "top": 175, "height": 29, "left": 165}, "words": "特别注意事项"}, {"probability": {"variance": 2e-06, "average": 0.998398, "min": 0.996935}, "location": {"width": 49, "top": 225, "height": 27, "left": 166}, "words": "出血"}, {"probability": {"variance": 0.0044, "average": 0.974491, "min": 0.725698}, "location": {"width": 918, "top": 270, "height": 30, "left": 167}, "words": " VEGFR抑制剂类抗肿瘤药物有可能增加出血的风险。在阿帕替尼的ⅡI、Ⅲ期临床研究中"}, {"probability": {"variance": 9e-06, "average": 0.998449, "min": 0.984268}, "location": {"width": 994, "top": 316, "height": 32, "left": 117}, "words": "排除了有胃肠道出血倾向的患者,未发现本品相对安慰剂组明显增加出血的风险。但仍应提醒"}, {"probability": {"variance": 5.6e-05, "average": 0.997046, "min": 0.953095}, "location": {"width": 991, "top": 365, "height": 32, "left": 118}, "words": "临床医生用药时密切关注。对合并用华法林抗凝的患者应常规监测凝血酶原时间(APTT)和"}, {"probability": {"variance": 0.000332, "average": 0.994419, "min": 0.916817}, "location": {"width": 875, "top": 413, "height": 31, "left": 117}, "words": "国际标准化比率(NR),并注意临床出血迹象,一旦发生出血迹象,应及时停药"}, {"probability": {"variance": 0.002659, "average": 0.988126, "min": 0.669333}, "location": {"width": 946, "top": 461, "height": 30, "left": 165}, "words": "对于重度(3/4级)出血的患者,建议暂停用药;如恢复用药后再次出现重度(3/4级)出"}, {"probability": {"variance": 0.004802, "average": 0.986778, "min": 0.566172}, "location": {"width": 926, "top": 510, "height": 30, "left": 119}, "words": "血,可下调一个剂量后继续用药(参见【用法用量》),如不良反应仍持续,建议停药"}, {"probability": {"variance": 0.001235, "average": 0.989597, "min": 0.759677}, "location": {"width": 943, "top": 558, "height": 32, "left": 166}, "words": "凝血功能异常(APTT>1.5×ULN或INR>1.5)的患者未被纳入阿帕替尼临床研究中,因此"}, {"probability": {"variance": 0.002182, "average": 0.989204, "min": 0.70473}, "location": {"width": 981, "top": 606, "height": 31, "left": 117}, "words": "尚不明确本部分人群使用阿帕替尼的风险。凝血功能异常患者应慎用本品,服用本品期间应严"}, {"probability": {"variance": 0.007146, "average": 0.985169, "min": 0.444351}, "location": {"width": 993, "top": 653, "height": 31, "left": 119}, "words": "密监测凝血酶原时间和国际标准化比率,一旦出现严重(3/4级)异常,建议暂停用药;如恢"}, {"probability": {"variance": 8e-06, "average": 0.998258, "min": 0.988977}, "location": {"width": 958, "top": 699, "height": 33, "left": 118}, "words": "复用药后再次出现严重(34级)异常,可下调一个剂量后继续用药(参见【用法用量】)"}, {"probability": {"variance": 0, "average": 0.999655, "min": 0.998897}, "location": {"width": 318, "top": 750, "height": 29, "left": 118}, "words": "如不良反应仍持续,建议停药"}, {"probability": {"variance": 2.3e-05, "average": 0.998289, "min": 0.9718}, "location": {"width": 946, "top": 794, "height": 32, "left": 167}, "words": "心脏毒性:临床研究中观察到服用阿帕替尼可能会引起心电图异常,包括QT间期延长或"}, {"probability": {"variance": 1.1e-05, "average": 0.997983, "min": 0.9803}, "location": {"width": 994, "top": 842, "height": 33, "left": 118}, "words": "窦性心动过缓。应慎用于已知有QT间期延长病史的患者、服用抗心律失常药物的患者或者有"}, {"probability": {"variance": 1e-06, "average": 0.999251, "min": 0.996939}, "location": {"width": 538, "top": 891, "height": 29, "left": 119}, "words": "相关基础心脏疾病、心动过缓和电解质紊乱的患者"}, {"probability": {"variance": 5e-06, "average": 0.998599, "min": 0.987691}, "location": {"width": 945, "top": 937, "height": 31, "left": 165}, "words": "用药期间应注意严密监测心电图和心脏功能。如发生34级不良反应,建议暂停用药;如"}, {"probability": {"variance": 0.000124, "average": 0.996184, "min": 0.937557}, "location": {"width": 987, "top": 984, "height": 33, "left": 117}, "words": "恢复用药后再次出现34级不良反应,可下调一个剂量后继续用药(参考表1的量调整原则)"}, {"probability": {"variance": 0.000156, "average": 0.994782, "min": 0.94642}, "location": {"width": 994, "top": 1029, "height": 40, "left": 118}, "words": "如不良反应仍持续,建议停药。对于出现ⅢIⅣ级心功能不全或心脏彩超检查显示左室射血分"}, {"probability": {"variance": 7e-06, "average": 0.997637, "min": 0.991998}, "location": {"width": 256, "top": 1084, "height": 31, "left": 117}, "words": "数<50%的患者建议停药"}, {"probability": {"variance": 3e-06, "average": 0.998935, "min": 0.992192}, "location": {"width": 949, "top": 1139, "height": 35, "left": 167}, "words": "肝脏毒性:临床研究中观察到服用阿帕替尼可引起一过性转氨酶升高或总胆红素升高。原"}, {"probability": {"variance": 7e-06, "average": 0.998488, "min": 0.989302}, "location": {"width": 998, "top": 1192, "height": 38, "left": 119}, "words": "有血清转氨酶和总胆红素升高的患者应慎用本品。尚未在肝功能不全人群中进行研究,既往有"}, {"probability": {"variance": 6e-06, "average": 0.998259, "min": 0.989144}, "location": {"width": 1001, "top": 1244, "height": 41, "left": 119}, "words": "肝功能不全患者当服用阿帕替尼时应谨慎和密切监测(建议在用药最初的两个月内定期如每2"}, {"probability": {"variance": 0.00231, "average": 0.989269, "min": 0.684838}, "location": {"width": 969, "top": 1299, "height": 40, "left": 121}, "words": "周检测一次肝功能)。重度肝功能不全患者禁用。当患者发生3/4级转氨酶和总胆红素升高时"}, {"probability": {"variance": 1e-06, "average": 0.999422, "min": 0.995118}, "location": {"width": 998, "top": 1354, "height": 39, "left": 120}, "words": "建议暂停用药,同时需监测血清转氨酶及总胆红素直至其水平明显下降后可恢复用药;如恢复"}, {"probability": {"variance": 0.004243, "average": 0.987622, "min": 0.574344}, "location": {"width": 998, "top": 1408, "height": 41, "left": 121}, "words": "用药后再次出现3/4级不良反应,可下调一个剂量后继续用药(参见【用法用量】),如不良"}, {"probability": {"variance": 1e-06, "average": 0.998916, "min": 0.996014}, "location": {"width": 245, "top": 1472, "height": 35, "left": 122}, "words": "反应仍持续,建议停药"}], "language": 3}